作者
Quincy S Chu, Derek J Jonker, Diane M Provencher, Wilson H Miller, Nathaniel Bouganim, Anthony Frank Shields, Geoffrey Shapiro, Michael B Sawyer, Stephanie Lheureux, Vanessa Samouelian, Walter H Gotlieb, Khashayar Esfahani, Sara L Zaknoen, Patricia S Smith, Joel Owen, Caroline Fortier, John R Stille, Darcy Vincett, Amit M Oza
发表日期
2020/5/20
来源
Journal of Clinical Oncology
卷号
38
期号
15_suppl
页码范围
3581-3581
出版商
American Society of Clinical Oncology
简介
3581
Background: LY2880070 (LY) is an oral, selective competitive inhibitor of checkpoint kinase 1 (Chk1). Chk1 inhibitors are known to increase the anti-tumor efficacy of agents such as gemcitabine (GEM), which induce replication stress. Synergy between these two agents has been applied to the clinical setting. Methods: This two-part, open-label multi-center study explores the safety, pharmacokinetics (PK), and anti-tumor activity of LY in patients with advanced or metastatic cancers. The primary objective of this study was to determine the maximum tolerated dose (MTD) for multiple escalating oral doses of LY in combination with GEM. Secondary objectives were to: 1) Characterize the dose-limiting toxicities (DLTs) and overall safety profile for LY; 2) Evaluate the PK of LY; and 3) Evaluate the anti-tumor activity of LY. Patients received LY in a variety of different dose regimens, in combination with GEM (50 to 800 …
学术搜索中的文章
QS Chu, DJ Jonker, DM Provencher, WH Miller… - 2020